Evaluation of the effects of thyroid function in patients with Graves disease after vaccination with COVID-19 and study of vaccine safety and efficacy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100050617

Enrollment

Unknown

Registered

2021-09-01

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' disease

Interventions

Graves disease group:None

healthy control group:None

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Graves' disease group. 1. Have or have had Graves' disease; 2. Aged 18 to 80 years; 3. Voluntary participation in the program. Healthy control group. 1. No history of Graves' disease; 2. Aged 18 to 80 years; 3. Voluntary participation in the program.

Exclusion criteria

Exclusion criteria: 1. HIV, HCV and other pathogens infection; 2. Previous history of neoconiosis/suspected case/close contact with neoconiosis patients; 3. Use of hormones, cyclosporine, immunoglobulin and other drugs that affect immunity in the last two months; 4. Contraindication to vaccination against Neocon ; 5. Concomitant factors such as acute inflammatory phase, malignancy, etc.

Design outcomes

Primary

Measure	Time frame
anti-SARS-CoV-2 antibody;Thyroid function;Thyroid autoantibodies;	—

Countries

China

Contacts

Public ContactLiu Dongfang

The Second Affiliated Hospital of Chongqing Medical University

300306@hospital.cqum.edu.cn+86 18623407751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026